Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$4.88
-0.13-2.50%
At close: -
$4.92
0.040.82%
After Hours: Apr 4, 4:20 PM EDT
Comments
Loading...
Phathom Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:PHAT | Benzinga
Phathom Pharmaceuticals Inc has a consensus price target of $22.71 based on the ratings of 9 analysts. The high is $30 issued by BMO Capital on March 1, 2023. The low is $12 issued by Goldman Sachs on March 10, 2025. The 3 most-recent analyst ratings were released by Needham, Goldman Sachs, and HC Wainwright & Co. on April 2, 2025, March 10, 2025, and March 7, 2025, respectively. With an average price target of $22.67 between Needham, Goldman Sachs, and HC Wainwright & Co., there's an implied 360.70% upside for Phathom Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Needham
Goldman Sachs
HC Wainwright & Co.
Stifel
Craig-Hallum
1calculated from analyst ratings
Analyst Ratings for Phathom Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/02/2025 | Buy Now | — | Guggenheim | Yatin Suneja47% | — | Reiterates | Buy → Buy | Get Alert |
| 04/02/2025 | Buy Now | 469.11% | Needham | Joseph Stringer47% | $28 → $28 | Reiterates | Buy → Buy | Get Alert |
| 03/10/2025 | Buy Now | 143.9% | Goldman Sachs | Paul Choi58% | $18 → $12 | Maintains | Neutral | Get Alert |
| 03/07/2025 | Buy Now | 469.11% | HC Wainwright & Co. | Matthew Caufield37% | $28 → $28 | Reiterates | Buy → Buy | Get Alert |
| 03/06/2025 | Buy Now | 469.11% | Needham | Joseph Stringer47% | $28 → $28 | Reiterates | Buy → Buy | Get Alert |
| 01/10/2025 | Buy Now | 469.11% | Needham | Joseph Stringer47% | $28 → $28 | Reiterates | Buy → Buy | Get Alert |
| 12/12/2024 | Buy Now | 469.11% | HC Wainwright & Co. | Matthew Caufield37% | $28 → $28 | Reiterates | Buy → Buy | Get Alert |
| 12/11/2024 | Buy Now | 469.11% | Needham | Joseph Stringer47% | $28 → $28 | Reiterates | Buy → Buy | Get Alert |
| 09/13/2024 | Buy Now | 428.46% | Needham | Joseph Stringer47% | $26 → $26 | Reiterates | Buy → Buy | Get Alert |
| 09/06/2024 | Buy Now | 428.46% | Needham | Joseph Stringer47% | $26 → $26 | Reiterates | Buy → Buy | Get Alert |
| 08/30/2024 | Buy Now | 428.46% | Needham | Joseph Stringer47% | $26 → $26 | Reiterates | Buy → Buy | Get Alert |
| 08/23/2024 | Buy Now | 428.46% | Needham | Joseph Stringer47% | $26 → $26 | Reiterates | Buy → Buy | Get Alert |
| 08/19/2024 | Buy Now | 428.46% | Needham | Joseph Stringer47% | $26 → $26 | Reiterates | Buy → Buy | Get Alert |
| 08/12/2024 | Buy Now | 469.11% | HC Wainwright & Co. | Matthew Caufield37% | $28 → $28 | Reiterates | Buy → Buy | Get Alert |
| 08/12/2024 | Buy Now | 428.46% | Needham | Joseph Stringer47% | $26 → $26 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2024 | Buy Now | 143.9% | Goldman Sachs | Paul Choi58% | $10 → $12 | Maintains | Neutral | Get Alert |
| 07/26/2024 | Buy Now | 428.46% | Needham | Joseph Stringer47% | $26 → $26 | Reiterates | Buy → Buy | Get Alert |
| 07/22/2024 | Buy Now | 428.46% | Needham | Joseph Stringer47% | $26 → $26 | Reiterates | Buy → Buy | Get Alert |
| 07/19/2024 | Buy Now | 469.11% | HC Wainwright & Co. | Matthew Caufield37% | $28 → $28 | Reiterates | Buy → Buy | Get Alert |
| 07/19/2024 | Buy Now | 428.46% | Needham | Joseph Stringer47% | $26 → $26 | Reiterates | Buy → Buy | Get Alert |
| 07/12/2024 | Buy Now | 428.46% | Needham | Joseph Stringer47% | $26 → $26 | Reiterates | Buy → Buy | Get Alert |
| 07/08/2024 | Buy Now | 428.46% | Needham | Joseph Stringer47% | $26 → $26 | Reiterates | Buy → Buy | Get Alert |
| 06/28/2024 | Buy Now | 428.46% | Needham | Joseph Stringer47% | $26 → $26 | Reiterates | Buy → Buy | Get Alert |
| 06/21/2024 | Buy Now | 428.46% | Needham | Joseph Stringer47% | $26 → $26 | Reiterates | Buy → Buy | Get Alert |
| 06/14/2024 | Buy Now | 428.46% | Needham | Joseph Stringer47% | $26 → $26 | Reiterates | Buy → Buy | Get Alert |
| 06/07/2024 | Buy Now | 428.46% | Needham | Joseph Stringer47% | $26 → $26 | Reiterates | Buy → Buy | Get Alert |
| 05/31/2024 | Buy Now | 428.46% | Needham | Joseph Stringer47% | $26 → $26 | Reiterates | Buy → Buy | Get Alert |
| 05/24/2024 | Buy Now | 428.46% | Needham | Joseph Stringer47% | $26 → $26 | Reiterates | Buy → Buy | Get Alert |
| 05/17/2024 | Buy Now | 428.46% | Needham | Joseph Stringer47% | $26 → $26 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2024 | Buy Now | 428.46% | Needham | Joseph Stringer47% | $26 → $26 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2024 | Buy Now | 469.11% | HC Wainwright & Co. | Matthew Caufield37% | $28 → $28 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2024 | Buy Now | 428.46% | Needham | Joseph Stringer47% | $26 → $26 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 428.46% | Needham | Joseph Stringer47% | $26 → $26 | Reiterates | Buy → Buy | Get Alert |
| 05/03/2024 | Buy Now | 428.46% | Needham | Joseph Stringer47% | $26 → $26 | Reiterates | Buy → Buy | Get Alert |
| 05/03/2024 | Buy Now | 387.8% | Stifel | Annabel Samimy66% | → $24 | Initiates | → Buy | Get Alert |
| 04/26/2024 | Buy Now | 428.46% | Needham | Joseph Stringer47% | $26 → $26 | Reiterates | Buy → Buy | Get Alert |
| 04/19/2024 | Buy Now | 428.46% | Needham | Joseph Stringer47% | $26 → $26 | Reiterates | Buy → Buy | Get Alert |
| 04/12/2024 | Buy Now | 428.46% | Needham | Joseph Stringer47% | $26 → $26 | Reiterates | Buy → Buy | Get Alert |
| 04/11/2024 | Buy Now | 428.46% | Needham | Joseph Stringer47% | $26 → $26 | Reiterates | Buy → Buy | Get Alert |
| 04/05/2024 | Buy Now | 428.46% | Needham | Joseph Stringer47% | $26 → $26 | Reiterates | Buy → Buy | Get Alert |
| 04/01/2024 | Buy Now | 428.46% | Needham | Joseph Stringer47% | $26 → $26 | Reiterates | Buy → Buy | Get Alert |
| 03/22/2024 | Buy Now | 428.46% | Needham | Joseph Stringer47% | $26 → $26 | Reiterates | Buy → Buy | Get Alert |
| 03/15/2024 | Buy Now | 428.46% | Needham | Joseph Stringer47% | $26 → $26 | Maintains | Buy | Get Alert |
| 03/08/2024 | Buy Now | 469.11% | HC Wainwright & Co. | Matthew Caufield37% | $28 → $28 | Reiterates | Buy → Buy | Get Alert |
| 03/08/2024 | Buy Now | 428.46% | Needham | Joseph Stringer47% | $26 → $26 | Reiterates | Buy → Buy | Get Alert |
| 03/07/2024 | Buy Now | 428.46% | Needham | Joseph Stringer47% | $26 → $26 | Reiterates | Buy → Buy | Get Alert |
| 02/23/2024 | Buy Now | 428.46% | Needham | Joseph Stringer47% | $26 → $26 | Reiterates | Buy → Buy | Get Alert |
| 02/16/2024 | Buy Now | 428.46% | Needham | Joseph Stringer47% | $26 → $26 | Reiterates | Buy → Buy | Get Alert |
| 02/09/2024 | Buy Now | 428.46% | Needham | Joseph Stringer47% | $26 → $26 | Reiterates | Buy → Buy | Get Alert |
| 01/05/2024 | Buy Now | 428.46% | Needham | Joseph Stringer47% | $23 → $26 | Maintains | Buy | Get Alert |
| 11/10/2023 | Buy Now | 367.48% | Needham | Joseph Stringer47% | → $23 | Reiterates | Buy → Buy | Get Alert |
| 11/03/2023 | Buy Now | 103.25% | Goldman Sachs | Paul Choi58% | $9 → $10 | Maintains | Neutral | Get Alert |
| 09/27/2023 | Buy Now | 367.48% | Needham | Joseph Stringer47% | → $23 | Reiterates | Buy → Buy | Get Alert |
| 08/11/2023 | Buy Now | 469.11% | HC Wainwright & Co. | Matthew Caufield37% | → $28 | Reiterates | Buy → Buy | Get Alert |
| 08/11/2023 | Buy Now | 367.48% | Needham | Joseph Stringer47% | → $23 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | Buy Now | 469.11% | HC Wainwright & Co. | Matthew Caufield37% | → $28 | Initiates | → Buy | Get Alert |
| 06/12/2023 | Buy Now | 367.48% | Needham | Joseph Stringer47% | → $23 | Reiterates | → Buy | Get Alert |
| 05/11/2023 | Buy Now | — | Evercore ISI Group | Umer Raffat43% | — | Upgrade | In-Line → Outperform | Get Alert |
| 04/19/2023 | Buy Now | 367.48% | Needham | Joseph Stringer47% | → $23 | Reiterates | → Buy | Get Alert |
| 04/05/2023 | Buy Now | 367.48% | Needham | Joseph Stringer47% | → $23 | Reiterates | → Buy | Get Alert |
| 03/13/2023 | Buy Now | 326.83% | Craig-Hallum | Chase Knickerbocker44% | → $21 | Initiates | → Buy | Get Alert |
| 03/01/2023 | Buy Now | 509.76% | BMO Capital | Gary Nachman57% | $35 → $30 | Maintains | Outperform | Get Alert |
| 02/10/2023 | Buy Now | 367.48% | Needham | Joseph Stringer47% | $25 → $23 | Maintains | Buy | Get Alert |
| 01/04/2023 | Buy Now | 611.38% | BMO Capital | Gary Nachman57% | $38 → $35 | Maintains | Outperform | Get Alert |
| 01/04/2023 | Buy Now | 408.13% | Needham | Joseph Stringer47% | $38 → $25 | Maintains | Buy | Get Alert |
| 11/14/2022 | Buy Now | 672.36% | BMO Capital | Gary Nachman57% | $45 → $38 | Maintains | Outperform | Get Alert |
| 11/11/2022 | Buy Now | 509.76% | Guggenheim | Yatin Suneja47% | $42 → $30 | Maintains | Buy | Get Alert |
| 10/21/2022 | Buy Now | 225.2% | Jefferies | Glen Santangelo50% | → $16 | Initiates | → Buy | Get Alert |
| 08/03/2022 | Buy Now | 82.93% | Goldman Sachs | Paul Choi58% | $15 → $9 | Maintains | Neutral | Get Alert |
| 08/03/2022 | Buy Now | 672.36% | Needham | Joseph Stringer47% | $44 → $38 | Maintains | Buy | Get Alert |
| 05/24/2022 | Buy Now | 204.88% | Goldman Sachs | Paul Choi58% | $32 → $15 | Maintains | Neutral | Get Alert |
| 05/06/2022 | Buy Now | — | Evercore ISI Group | Umer Raffat43% | — | Downgrade | Outperform → In-Line | Get Alert |
FAQ
What is the target price for Phathom Pharmaceuticals (PHAT) stock?
The latest price target for Phathom Pharmaceuticals (NASDAQ:PHAT) was reported by Guggenheim on April 2, 2025. The analyst firm set a price target for $0.00 expecting PHAT to fall to within 12 months (a possible -100.00% downside). 39 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Phathom Pharmaceuticals (PHAT)?
The latest analyst rating for Phathom Pharmaceuticals (NASDAQ:PHAT) was provided by Guggenheim, and Phathom Pharmaceuticals reiterated their buy rating.
When was the last upgrade for Phathom Pharmaceuticals (PHAT)?
The last upgrade for Phathom Pharmaceuticals Inc happened on May 11, 2023 when Evercore ISI Group raised their price target to N/A. Evercore ISI Group previously had an in-line for Phathom Pharmaceuticals Inc.
When was the last downgrade for Phathom Pharmaceuticals (PHAT)?
The last downgrade for Phathom Pharmaceuticals Inc happened on May 6, 2022 when Evercore ISI Group changed their price target from N/A to N/A for Phathom Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Phathom Pharmaceuticals (PHAT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Phathom Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Phathom Pharmaceuticals was filed on April 2, 2025 so you should expect the next rating to be made available sometime around April 2, 2026.
Is the Analyst Rating Phathom Pharmaceuticals (PHAT) correct?
While ratings are subjective and will change, the latest Phathom Pharmaceuticals (PHAT) rating was a reiterated with a price target of $0.00 to $0.00. The current price Phathom Pharmaceuticals (PHAT) is trading at is $4.92, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.